Background Highly effective human papillomavirus (HPV) vaccines are used in many
national programs in 3-or 2-dose schedules. We examined HPV vaccine effectiveness …

Human papillomavirus (HPV) infection is highly prevalent and can lead to cancer; the
development of safe and efficacious vaccines for HPV is a major public health concern. The …

Background Previously, we demonstrated similar human papillomavirus (HPV) 16/18
vaccine efficacy estimates and stable HPV16/18 antibody levels four years postvaccination …

Cervical and other anogenital cancers are initiated by infection with one of a small group of
human papillomaviruses (HPV). Virus-like particle-based vaccines have recently been …

Background Effective vaccination against HPV 16 and HPV 18 to prevent cervical cancer will
require a high level of sustained protection against infection and precancerous lesions. Our …

Cervical cancer is an important public health problem worldwide, and especially in
developing countries. The link between cervical cancer and oncogenic human …

Background Vaccination against the most common oncogenic human papillomavirus (HPV)
types, HPV-16 and HPV-18, could prevent development of up to 70% of cervical cancers …

BACKGROUND: Cervical cancer is one of the most common types of cancer in women and
is largely attributable to persistent infection with high-oncogenic risk human papillomavirus …

Background A randomised double-blind placebo-controlled phase II study was done to
assess the efficacy of a prophylactic quadrivalent vaccine targeting the human …

Background The investigational 9-valent viruslike particle vaccine against human
papillomavirus (HPV) includes the HPV types in the quadrivalent HPV (qHPV) vaccine (6 …